



Cite this: RSC Adv., 2017, 7, 26060

Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-*d*]pyrimidine scaffold†

 Qiumeng Zhang,^{‡,a} Luyao Zhang,^{‡,bc} Jie Yu,^a Heng Li,^{bc} Shijun He,^{bc} Wei Tang,^{bc} Jianping Zuo^{*bc} and Wei Lu  ^{a*}

A series of 4,6-substituted thieno[3,2-*d*]pyrimidine derivatives as Bruton's tyrosine kinase (BTK) inhibitors are designed, synthesized and evaluated for their enzymatic inhibition and immunosuppressive activities. These derivatives exhibit varying inhibitory activities against BTK *in vitro*. Compound **8** is a novel potent BTK inhibitor which has an IC_{50} value of 29.9 nM, exerts excellent immunosuppressive activity by inhibiting the proliferation of B cells (IC_{50} = 284 nM), and shows low cytotoxicity (CC_{50} = 53 632 nM) on murine splenocytes. In addition, compound **8** displays considerable selectivity between T cells (IC_{50} > 10 μ M) and B cells. Furthermore, enzymatic assays on more than twenty kinases confirm that compound **8** is more selective than the reference compound Olmutinib. In summary, the results suggest that compound **8** is a potential BTK inhibitor for further evaluation and modification of the C-4 and C-6 position of the thieno[3,2-*d*]pyrimidine scaffold, which could be considered a new strategy in the development of BTK inhibitors.


Received 15th April 2017
 Accepted 2nd May 2017

DOI: 10.1039/c7ra04261b
rsc.li/rsc-advances

Introduction

Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that belongs to the Tec kinase family,^{1,2} which is expressed primarily in immune cells including B cells, monocytes, neutrophils, mast cells and macrophages.^{3,4} Recently, significant progress has been made in understanding the function and regulation of BTK in multiple signaling pathways,^{5–10} such as the B cells receptor (BCR) signaling¹¹ and Fc γ receptor (FCR) signaling pathways.¹² BTK plays a critical role in B cell development, including proliferation, differentiation, maturation, activation and survival. In the past decades, BTK inhibitors have been considered as a therapeutic option for the treatment of B cell malignancies.^{13–21} Ibrutinib, which is a selective irreversible BTK inhibitor, has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and

Waldenstrom's macroglobulinemia.^{9,12–24} Besides, B cells have been recognized to play a pivotal role in regulating immune responses and BTK inhibitors have been proven to be effective in treating autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).^{25,26} Several BTK inhibitors have been reported in the clinical development for the treatment of RA or SLE,^{22,27–33} including Ibrutinib, Olmutinib, Spebrutinib, and Acalabrutinib (Fig. 1).



^aSchool of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China. E-mail: wlu@chem.ecnu.edu.cn; Tel: +86-21-62238771

^bLaboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China. E-mail: jpzuo@simm.ac.cn; Tel: +86-21-50801659

^cUniversity of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China

† Electronic supplementary information (ESI) available: General HPLC methods, spectrum of the corresponding compounds and the IC_{50} curves of compounds **7**, **8** and Olmutinib against BTK and EGFR. See DOI: [10.1039/c7ra04261b](https://doi.org/10.1039/c7ra04261b)

‡ These authors contributed equally.

Fig. 1 Chemical structures of some clinical BTK inhibitors used in the treatment RA or SLE.



To date, thieno[3,2-*d*]pyrimidine derivatives have attracted a great deal of attention due to their broad spectrum of biological activities, including antitumor, anti-autoimmune, and antifungal activities. Over the past decades, numerous studies have resulted in vast literature on the modification of the thieno[3,2-*d*]pyrimidine core. These thieno[3,2-*d*]pyrimidines exhibit remarkable biological functions by targeting different kinases, such as EGFR, VEGFR, mTOR, PI₃K, BTK, HDAC and SIRT (Fig. 2).³⁴⁻⁴⁶ Among the reported thieno[3,2-*d*]pyrimidine derivatives, Olmutinib, which is a 2,4-substituted thieno[3,2-*d*]pyrimidine, is being developed as an EGFR inhibitor⁴⁷ for the treatment of non-small cell lung cancer and as a BTK inhibitor²⁷ for autoimmune disorders.

We are interested in developing BTK inhibitors for the treatment of autoimmune diseases and thus attracted to the broad spectrum activities of thieno[3,2-*d*]pyrimidine derivatives. Therefore, a series of novel thieno[3,2-*d*]pyrimidine based BTK inhibitors are designed by extending the C-2 substitution of Olmutinib to the C-6 position of our thieno[3,2-*d*]pyrimidine derivatives using an angle-changing strategy. Considering the space length, the substituents are attached to the thiophene ring through the C-C bond. An electrophilic warhead is essential for irreversible BTK inhibitors to form a covalent bond with Cys481 of BTK, thus the C-4 substitution of Olmutinib is kept on the C-4 position of our thieno[3,2-*d*]pyrimidine derivatives. The results show that most of the synthesized compounds exhibit weak potency against BTK, whereas compounds **7** and **8** are equipotent to Olmutinib. In addition, it is exciting that compounds **7** and **8** are ineffective in inhibiting EGFR. Thus, high selectivity between BTK and EGFR could be achieved by compounds with the 4,6-substituted thieno[3,2-*d*]pyrimidine scaffold. Herein, we describe the design, synthesis and preliminary activities of the compounds related to the general structure **A** (Fig. 3).




Fig. 2 Chemical structures of some thieno[3,2-*d*]pyrimidines




Fig. 3 Design of 4,6-substituted thieno[3,2-*d*]pyrimidines


Results and discussion

Chemistry

The detailed synthetic strategy to target compounds **4–20** is illustrated in Scheme 1. Compound **1** was prepared according to published procedures.^{48,49} Intermediates **2** and **3** were obtained from compound **1** through nucleophilic substitution with 3-nitrophenol and 6-nitroindoline, respectively. Compounds **4a–20a** were assembled *via* the following two steps from **2** or **3**: (i) Suzuki coupling between intermediates **2/3** and the corresponding boric acid/boric acid ester and (ii) reduction of nitro with RANEY®-Ni under H_2 . Finally, **4a–20a** were reacted with acryloyl chloride to obtain the targets **4–20**. Some of the intermediates and final targets have poor solubility, especially **3, 14, 16, 17, 18** and **20**.

Biological evaluation

First, the 4,6-substituted thieno[3,2-*d*]pyrimidine derivatives were evaluated for their activities against BTK using the LanthaScreen® Tb Kinase Activity Assay. The results were



Scheme 1 Synthesis of target compounds 4–20. Reagents and conditions: (a) 3-nitrophenol, Cs_2CO_3 , anhydrous DMF, rt, 96%; (b) 6-nitroindoline, trifluoroacetic acid, isopropyl alcohol, 80 °C, 93%; (c) $\text{Pd}(\text{dpdpf})\text{Cl}_2\text{-DCM}$, Na_2CO_3 , corresponding boric acid or boric acid ester, THF, water, 80 °C, N_2 , overnight; (d) RANEY®-Ni, H_2 , MeOH, rt, overnight; and (e) acryloyl chloride, NaHCO_3 , THF, water, 0 °C.

expressed as IC_{50} values and are summarized in Tables 1 and 2. Compound **4**, which was obtained by evolving the C-2 substitution of Olmutinib to the C-6 position, was approximately 215-fold less potent than Olmutinib. Among the tested compounds, **7** and **8** were the most potent BTK inhibitors which had IC_{50} values of 11.9 nM and 29.9 nM, respectively. Apparently, they are equipotent to Olmutinib ($IC_{50} = 13.9$ nM) in suppressing BTK activity. Moreover, when the C-4 position of **8** was replaced by *N*-(indolin-6-yl)acrylamide, the BTK inhibitory activities of compound **15** disappeared ($IC_{50} > 10\,000$ nM). Besides, most of the compounds shown in Table 2 exhibit negligible activities against BTK. These results suggest that substitution of the indoline ring at the C-4 position is unfavorable for the interaction with BTK. In addition, the wide varieties of activities shown in Table 1, which range from 11.9 nM to more than

Table 1 The inhibitory activities of the phenol substituted derivatives against BTK

Comp.	R_1	BTK enzymatic assay ^a IC_{50} (nM)	
4		2980 ± 975	
5		2151 ± 984	
6		249.3 ± 34	
7		11.9 ± 1.1	
8		29.9 ± 8.2	
9		$>10\,000$	
10		$>10\,000$	
11		1494 ± 657	
12		$>10\,000$	
13		$>10\,000$	
Olmutinib ^b	—	13.9 ± 5.6	

^a The data were analysed in duplicate and shown as mean \pm SE. ^b Used as the positive control.

Table 2 The inhibitory activities of the indoline substituted derivatives against BTK

Comp.	R_2	BTK enzymatic assay ^a IC_{50} (nM)
14		3688 ± 1135
15		$>10\,000$
16		650 ± 124
17		$>10\,000$
18		$>10\,000$
19		$>10\,000$
20		$>10\,000$
Olmutinib ^b	—	13.9 ± 5.6

^a The data were analyzed in duplicate and shown as mean \pm SE. ^b Used as the positive control.

10 000 nM, indicating that BTK is sensitive to the substitution at the C-6 position.

Based on the overall profile of this series, compounds **7** and **8** were selected for further profiling because of their excellent enzymatic potency. Since the structures of **7** and **8** were similar with the dual BTK and EGFR inhibitor Olmutinib, the EGFR kinase activity assay was performed. As shown in Table 3, compounds **7** and **8** were ineffective in inhibiting EGFR ($IC_{50} > 10\,000$ nM). The high selectivity between BTK and EGFR of **7** and **8** is beneficial in the treatment of autoimmune diseases.

In order to evaluate the immunosuppressive activity of compounds **7** and **8**, the nonspecific toxicity of murine splenocytes was determined using a Cell Counting Kit-8 (CCK-8) and lymphocytes proliferation responses were determined using the ^3H -TdR incorporation method. Also, concanavalin A (Con A)

Table 3 The inhibitory activities of compounds **7** and **8** against EGFR

Comp.	BTK IC_{50} ^a (nM)	EGFR IC_{50} (nM)	SI
7	11.9 ± 1.1	$>10\,000$	>844
8	29.9 ± 8.2	$>10\,000$	>334
Olmutinib	13.9 ± 5.6	17.6 ± 6.4	1.3

^a The results of IC_{50} shown as mean \pm SE.



Table 4 Cytotoxicity and proliferation response of murine lymphocytes

Compound	Cytotoxicity ^a		Proliferative responses of murine lymphocytes ^a		
	CC ₅₀ (nM)	IC ₅₀ (nM)		IC ₅₀ (nM)	
		Con A stimulation	SI	LPS stimulation	SI
7	557	4507	0.1	183	3.0
8	53 632	>10 000	<5.4	284	188
Olmutinib	1489	1426	1.0	300	5.0
Ibrutinib	800	1829	0.4	86	9.3

^a The data were analysed in duplicate.




Fig. 4 Enzyme inhibition screen of **8** and Olmutinib against twenty-five selected kinases.

and lipopolysaccharide (LPS), which induce the proliferation of T cells and B cells, respectively, were used. The results are summarized in Table 4. Interestingly, compound 7 exhibits high cytotoxicity with a CC₅₀ value of 557 nM, however, its toxicity was greatly reduced when the C-6 position substituents of *p*-methylpiperazinephenyl was converted into *p*-methanesulfonylphenyl (**8**, CC₅₀ = 53 632 nM). Besides, **7** and **8** show potent inhibition against B cells (184 nM and 284 nM, respectively) but are ineffective against T cells (4507 nM and >10 000 nM, respectively). Considering that BTK mediates signaling pathways downstream of BCR in B cells,⁵⁰ not T cells, the immunosuppressive results are reasonable. In summary, **7** is confirmed to possess no immunosuppressive activity against B cells due to its high cytotoxicity, and **8** exhibits excellent immunosuppressive activity by inhibiting B cells compared with Olmutinib and Ibrutinib.

Furthermore, we screened the inhibitory activities of compound **8** against twenty-five selected kinases related to the SRC kinase family, JAK family, MAPK family and others. Compound **8** and Olmutinib were measured at single concentration of 200 nM in duplicate. As presented in Fig. 4, Olmutinib exhibits potent inhibition of JAK3, EGFR, ITK, BLK and BTK at 200 nM. Compound **8** has a negligible impact on most of the tested kinases except BTK and BLK, which indicates that compound **8** has relatively better kinase selectivity than Olmutinib.

Conclusion

In summary, a series of 4,6-substituted thieno[3,2-*d*]pyrimidines were designed and synthesized. Among the derivatives,

compounds **7** and **8** with IC₅₀ values of 11.9 nM and 29.9 nM, respectively, exhibit potent anti-BTK activity that is equipotent to Olmutinib. Due to the fact that BTK plays a critical role in B cell derived diseases, the nonspecific toxicity and proliferation responses of murine splenocytes were analyzed. Compound **8** exhibits excellent immunosuppressive activity by inhibiting B cell proliferation (IC₅₀ = 284 nM) and low cytotoxicity (CC₅₀ = 53 632 nM). Furthermore, the enzymatic inhibition screen assays on more than twenty kinases confirm that compound **8**, which has negligible activities for EGFR, JAK3, and ITK, is more selective than the reference compound Olmutinib. These preliminary results suggest that compound **8** is a novel promising BTK inhibitor for further evaluation and modification of the 4,6-substituted thieno[3,2-*d*]pyrimidine scaffold could be applied in the development of novel BTK inhibitors.

Experimental

Material and methods

All reagents and solvents were purchased from suppliers and purified/dried if an anhydrous solvent was necessary. Mass spectra (MS) were recorded on a Waters SDQ mass spectrometer and high resolution mass spectra (HRMS) were recorded on a Waters SYNAPT G2 ESI-TOF-MS analyzer. ¹H NMR spectra and ¹³C NMR spectra were recorded in CDCl₃, MeOD, CF₃COOD, D₂O and DMSO-d₆ on a Bruker DRX-400 (400 MHz) using TMS as the internal standard. Chemical shifts are reported as δ (ppm) and spin–spin coupling constants as J (Hz) values. Melting points were taken on a SGW X-4 melting point apparatus, uncorrected and reported in degrees centigrade. Column chromatography was performed with silica gel (200–300 mesh). The purity of all tested compounds was established by HPLC to be >95%.

Synthetic procedures

6-Bromo-4-chlorothieno[3,2-*d*]pyrimidine (1). Compound **1** was prepared according to ref.^{48 and 49}; white crystal; mp: 138.1–138.9 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 1H), 7.61 (s, 1H); ESI-MS: *m/z* 248.9 [M + H]⁺.

6-Bromo-4-(3-nitrophenoxy)thieno[3,2-*d*]pyrimidine (2). Compound **1** (2.49 g, 10 mmol), 3-nitrophenol (1.39 g, 10 mmol) and Cs₂CO₃ (6.52 g, 20 mmol) were mixed and anhydrous DMF (50 mL) was added subsequently. The solution was stirred at



room temperature for 2 h (monitored by TLC). Subsequently, the mixture was poured into ice water (500 mL) and a white solid precipitated slowly. The precipitate was collected, washed with water and dried to give the desired product 2 (3.4 g, 96%); white solid; mp: 174.0–174.6 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.72 (s, 1H), 8.31 (s, 1H), 8.22 (d, *J* = 8.1 Hz, 1H), 7.99 (s, 1H), 7.89 (d, *J* = 8.2 Hz, 1H), 7.82 (d, *J* = 8.2 Hz, 1H); ¹³C NMR (101 MHz, DMSO-d₆) δ 162.7, 161.7, 154.6, 151.7, 148.5, 131.1, 129.1, 127.7, 126.6, 121.2, 118.7, 117.6; ESI-MS: *m/z* 352.0 [M + H]⁺.

6-Bromo-4-(6-nitroindolin-1-yl)thieno[3,2-*d*]pyrimidine (3). Trifluoroacetic acid (1.5 mL, 20 mmol) was added to a solution of compound 1 (2.49 g, 10 mmol) and 6-nitroindoline (1.64 g, 10 mmol) in isopropyl alcohol (100 mmol). The resulting mixture was heated to 80 °C for 5 h. Subsequently, the reaction mixture was cooled to room temperature and then poured into ice water, and yellow solid precipitated slowly. The precipitate was collected, washed with water and dried to provide the desired product 3 (3.5 g, 93%); yellow solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆ + CF₃COOD) δ 9.26 (s, 1H), 8.62 (d, *J* = 8.7 Hz, 1H), 7.88 (s, 1H), 7.48 (d, *J* = 8.9 Hz, 1H), 7.31 (s, 1H), 4.62 (s, 2H), 3.32 (s, 2H); HRMS (ESI) *m/z* calcd for chemical formula: C₁₄H₉BrN₄O₂S [M + H]⁺: 376.9702, found: 376.9726.

General procedure for the synthesis of compounds 4–20

Step 1. A solution of compound 2 or 3 (0.5 mmol), corresponding boric acid or boric acid ester (0.75 mmol) and Pd(dppf)Cl₂-DCM (41 mg, 0.05 mmol) in THF (10 mL) was degassed with N₂ for 5 min followed by the addition Na₂CO₃ (106 mg, 0.5 M in water) under a continuous flow of nitrogen. The reaction mixture was stirred at 70 °C until the reaction was complete (monitored by TLC). The reaction mixture was allowed to cool to room temperature and then filtered. The filter cake was washed with water and DCM several times to afford the crude product (poor solubility). The crude product was suspended in methanol (30 mL) and then the mixture was purged with N₂. RANEY®-Ni was added and the mixture was purged with N₂ again, then H₂. The resulting solution was stirred at room temperature overnight. MeOH (20 mL) and DCM (50 mL) were added and the solution was filtered and concentrated *in vacuo* to afford 4a–20a, which were used directly in the next step.

Step 2. Corresponding 4a–20a (0.1 mmol) was dissolved or suspended in THF (10 mL) and then NaHCO₃ (0.2 mmol, 2 M in water) was added. Subsequently, acryloyl chloride (0.11 mmol, 1 M in anhydrous THF) was added to the solution dropwise at 0 °C. The resulting mixture was stirred for 1 h (monitored by TLC). Then EA (20 mL) and water (30 mL) were added and the layers were partitioned and separated. The organic layers were washed with NH₄Cl solution, then washed with water and brine, and dried over anhydrous sodium sulfate. The filtrate was concentrated and crystallized from MeOH/CH₂Cl₂/hexane to give the corresponding product 4–20.

3-((6-(4-Phenoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)aniline (4a). From compound 2 (176 mg, 0.5 mmol) and (4-phenoxyphenyl)boronic acid (161 mg, 0.75 mmol), as that described in step 1, gave 4a (95 mg, 46%); off-white solid; mp: 152.2–153.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.71 (s, 1H), 7.72 (d, *J* = 8.4 Hz, 2H), 7.62 (s, 1H), 7.39 (t, *J* = 7.7 Hz, 2H), 7.20 (dt, *J* = 14.8, 7.7 Hz, 2H), 7.09 (d, *J* = 7.8 Hz, 4H), 6.69–6.54 (m, 3H), 3.81

(s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 164.0, 163.6, 159.3, 156.1, 154.9, 153.1, 152.9, 148.0, 130.4, 130.0, 128.4, 127.7, 124.2, 119.7, 119.1, 118.8, 117.2, 112.9, 111.5, 108.4; ESI-MS: *m/z* 412.1 [M + H]⁺.

N-((3-((6-(4-Phenoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)phenyl)acrylamide (4). From compound 4a (41 mg, 0.1 mmol), as that described in step 2, gave 4 (21 mg, 45%); off-white solid; mp: 214.2–214.9 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.39 (s, 1H), 8.70 (s, 1H), 8.07 (s, 1H), 7.99 (d, *J* = 8.5 Hz, 2H), 7.78 (s, 1H), 7.53 (d, *J* = 8.3 Hz, 1H), 7.46 (q, *J* = 7.6 Hz, 3H), 7.24 (t, *J* = 7.3 Hz, 1H), 7.14 (d, *J* = 8.3 Hz, 4H), 7.07 (d, *J* = 8.0 Hz, 1H), 6.44 (dd, *J* = 17.0, 10.0 Hz, 1H), 6.26 (d, *J* = 16.8 Hz, 1H), 5.83–5.73 (m, 1H); ¹³C NMR (101 MHz, DMSO-d₆) δ 163.9, 163.4, 162.9, 158.8, 155.6, 154.6, 152.2, 151.9, 140.3, 131.5, 130.3, 129.9, 128.6, 127.4, 127.0, 124.4, 119.5, 119.4, 118.7, 116.9, 116.8, 116.0, 112.7; HPLC: room temperature, *t*_g = 17.03 min, UV₂₅₄ = 97%; HRMS (ESI) *m/z* calcd for C₂₇H₁₉N₃O₃S [M + Na]⁺: 488.1045, found: 488.1054.

3-((6-(4-(2-Methoxyethoxy)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)aniline (5a). From compound 2 (176 mg, 0.5 mmol) and 2-(4-(2-methoxyethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (209 mg, 0.75 mmol), as that described in step 1, gave 5a (83 mg, 42%); off-white solid; mp: 172.4–173.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H), 7.70 (d, *J* = 7.8 Hz, 2H), 7.59 (s, 1H), 7.23 (s, 1H), 7.03 (d, *J* = 7.7 Hz, 2H), 6.62 (dd, *J* = 18.1, 7.7 Hz, 3H), 4.19 (s, 2H), 3.80 (s, 4H), 3.48 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 164.1, 163.6, 160.4, 154.8, 153.4, 153.2, 148.0, 130, 128.2, 125.8, 118.4, 117.0, 115.3, 112.9, 111.5, 108.4, 70.9, 67.5, 59.3; ESI-MS: *m/z* 394.0 [M + H]⁺.

N-((3-((6-(4-(2-Methoxyethoxy)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)phenyl)acrylamide (5). From compound 5a (39 mg, 0.1 mmol), as that described in step 2, gave 5 (18 mg, 40%); white solid; mp: 204.1–205.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.69 (s, 1H), 7.73 (s, 2H), 7.71 (s, 1H), 7.61 (s, 1H), 7.49 (s, 1H), 7.41 (s, 2H), 7.04 (d, *J* = 8.2 Hz, 3H), 6.43 (d, *J* = 16.7 Hz, 1H), 6.23 (dd, *J* = 16.8, 10.2 Hz, 1H), 5.78 (d, *J* = 10.2 Hz, 1H), 4.20 (s, 2H), 3.80 (s, 2H), 3.48 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 164.2, 163.4, 160.4, 154.5, 153.7, 152.5, 139.2, 130.9, 130.1, 128.2, 125.8, 118.4, 115.3, 70.9, 67.5, 59.3; HPLC: room temperature, *t*_g = 10.69 min, UV₃₂₀ = 98%; HRMS (ESI) *m/z* calcd for chemical formula: C₂₄H₂₁N₃O₄S [M + Na]⁺: 470.1150, found: 470.1152.

3-((6-(4-Morpholinophenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)aniline (6a). From compound 2 (176 mg, 0.5 mmol) and 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine (217 mg, 0.75 mmol), as that described in step 1, gave 6a (103 mg, 51%); white solid; mp: 227.2–228.3 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.69 (s, 1H), 7.69 (d, *J* = 8.8 Hz, 2H), 7.58 (s, 1H), 7.22 (d, *J* = 8.0 Hz, 1H), 6.97 (d, *J* = 8.8 Hz, 2H), 6.62 (ddd, *J* = 17.2, 7.2, 1.7 Hz, 3H), 3.95–3.84 (m, 4H), 3.80 (s, 2H), 3.31–3.24 (m, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 164.2, 163.5, 154.7, 153.8, 153.2, 152.3, 148.0, 130.3, 127.8, 123.9, 117.6, 116.7, 115.1, 112.8, 111.6, 108.4, 66.7, 48.3; ESI-MS: *m/z* 404.9 [M + H]⁺.

N-((3-((6-(4-Morpholinophenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)phenyl)acrylamide (6). From compound 6a (40 mg, 0.1 mmol), as that described in step 2, gave 6 (19 mg, 41%); yellow solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 8.64 (s, 1H), 7.91 (s, 1H), 7.80 (d, *J* = 8.7 Hz, 2H), 7.76 (s, 1H), 7.52 (d, *J* =



8.3 Hz, 1H), 7.43 (t, J = 8.1 Hz, 1H), 7.06 (d, J = 8.9 Hz, 3H), 6.43 (dd, J = 17.0, 10.1 Hz, 1H), 6.26 (dd, J = 17.0, 1.6 Hz, 1H), 5.82–5.73 (m, 1H), 3.81–3.67 (m, 4H), 3.29–3.20 (m, 4H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 164.3, 163.4, 162.7, 154.4, 153.5, 152.2, 152.0, 140.3, 131.6, 129.9, 127.6, 127.3, 122.1, 117.3, 116.9, 116.7, 115.1, 114.6, 112.7, 65.9, 47.3; HPLC: room temperature, t_g = 10.60 min, UV₂₅₄ = 98%; HRMS (ESI) m/z calcd for chemical formula: C₂₅H₂₂N₄O₃S [M + Na]⁺: 481.1310, found: 481.1312.

3-((6-(4-Methylpiperazin-1-yl)phenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)aniline (7a). From compound 2 (176 mg, 0.5 mmol) and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine (227 mg, 0.75 mmol), as that described in step 1, gave 7a (79 mg, 38%); yellow solid; mp: 228.5–229.3 °C; ^1H NMR (400 MHz, CDCl₃) δ 8.68 (s, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.56 (s, 1H), 7.22 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 8.8 Hz, 2H), 6.70–6.52 (m, 3H), 3.80 (s, 2H), 3.45–3.30 (m, 4H), 2.66–2.56 (m, 4H), 2.39 (s, 3H); ^{13}C NMR (101 MHz, CDCl₃) δ 164.2, 163.5, 154.7, 154.0, 153.2, 152.2, 148.0, 130.3, 127.8, 123.5, 117.4, 116.6, 115.4, 112.8, 111.6, 108.4, 54.8, 47.9, 46.0; ESI-MS: m/z 418.2 [M + H]⁺.

N-(3-((6-(4-Methylpiperazin-1-yl)phenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)phenylacrylamide (7). From compound 7a (42 mg, 0.1 mmol), as that described in step 2, gave 7 (19 mg, 41%); yellow solid; mp: 233.1–233.5 °C; ^1H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 8.65 (s, 1H), 7.91 (s, 1H), 7.78 (dd, J = 9.1, 5.4 Hz, 3H), 7.53 (d, J = 8.1 Hz, 1H), 7.44 (t, J = 8.1 Hz, 1H), 7.05 (d, J = 8.8 Hz, 3H), 6.44 (dd, J = 17.0, 10.1 Hz, 1H), 6.27 (dd, J = 17.0, 1.8 Hz, 1H), 5.78 (dd, J = 10.1, 1.8 Hz, 1H), 3.30 (dd, J = 12.6, 7.9 Hz, 6H), 2.56–2.37 (m, 8H), 2.23 (s, 3H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 164.3, 163.3, 162.7, 154.4, 153.5, 152.1, 152.0, 140.3, 131.6, 129.9, 127.6, 127.3, 121.6, 117.1, 116.8, 116.6, 115.1, 114.8, 112.7, 54.3, 47.0, 45.7; HPLC: room temperature, t_g = 7.60 min, UV₂₅₄ = 97%; HRMS (ESI) m/z calcd for chemical formula: C₂₆H₂₅N₅O₂S [M + Na]⁺: 494.1627, found: 494.1645.

3-((6-(4-(Methylsulfonyl)phenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)aniline (8a). From compound 2 (176 mg, 0.5 mmol) and (4-(methylsulfonyl)phenyl)boronic acid (150 mg, 0.75 mmol), as that described in step 1, gave 8a (93 mg, 47%); off-white solid; mp: >250 °C; ^1H NMR (400 MHz, DMSO-d₆) δ 8.74 (s, 1H), 8.28 (d, J = 13.9 Hz, 1H), 8.21 (d, J = 7.9 Hz, 2H), 8.07 (d, J = 7.9 Hz, 2H), 7.10 (t, J = 7.9 Hz, 1H), 6.56–6.39 (m, 3H), 5.35 (s, 2H), 3.30 (s, 3H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 163.4, 163.2, 154.9, 152.7, 150.3, 150.0, 141.7, 136.8, 129.8, 128.1, 127.5, 122.5, 117.2, 111.6, 108.5, 106.7, 43.4; ESI-MS: m/z 397.9 [M + H]⁺.

N-(3-((6-(4-(Methylsulfonyl)phenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide (8). From compound 8a (40 mg, 0.1 mmol), as that described in step 2, gave 8 (15 mg, 33%); yellow solid; mp: >250 °C; ^1H NMR (400 MHz, DMSO-d₆) δ 10.36 (s, 1H), 8.76 (s, 1H), 8.35 (s, 1H), 8.26 (d, J = 8.4 Hz, 2H), 8.09 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 1.8 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 8.1 Hz, 1H), 7.09 (dd, J = 7.9, 1.5 Hz, 1H), 6.44 (dd, J = 17.0, 10.1 Hz, 1H), 6.27 (dd, J = 17.0, 1.8 Hz, 1H), 5.82–5.74 (m, 1H), 3.31 (s, 3H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 163.4, 163.4, 163.2, 154.8, 151.8, 150.2, 141.7, 140.3, 136.7, 131.6, 129.9, 128.1, 127.5, 127.3, 122.6, 117.2, 116.9, 112.7, 43.4; HPLC: room temperature, t_g = 9.18 min, UV₂₅₄ = 96%; HRMS (ESI) m/z calcd for chemical formula: C₂₂H₁₇N₃O₄S₂ [M + Na]⁺: 474.0558, found: 474.0576.

3-((6-(3,5-Dimethoxyphenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)aniline (9a). From compound 2 (176 mg, 0.5 mmol) and (3,5-dimethoxyphenyl)boronic acid (137 mg, 0.75 mmol), as that described in step 1, gave 9a (120 mg, 63%); white solid; mp: 204.1–204.9 °C; ^1H NMR (400 MHz, DMSO-d₆) δ 8.70 (s, 1H), 8.15 (s, 1H), 7.10 (t, J = 8.0 Hz, 1H), 7.05 (d, J = 2.2 Hz, 2H), 6.65 (t, J = 2.1 Hz, 1H), 6.52 (dd, J = 8.1, 1.3 Hz, 1H), 6.46 (t, J = 2.1 Hz, 1H), 6.41 (dd, J = 7.8, 1.8 Hz, 1H), 5.34 (s, 2H), 3.85 (s, 6H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 163.4, 163.2, 161.1, 154.7, 152.7, 152.3, 150.3, 134.0, 129.8, 120.7, 116.3, 111.6, 108.5, 106.8, 104.7, 101.9, 79.1, 55.5; ESI-MS: m/z 380.1 [M + H]⁺.

N-(3-((6-(3,5-Dimethoxyphenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide (9). From compound 9a (43 mg, 0.1 mmol), as that described in step 2, gave 9 (17 mg, 39%); white solid; mp: 222.1–222.5 °C; ^1H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 8.72 (s, 1H), 8.25–8.12 (m, 1H), 7.79 (s, 1H), 7.53 (d, J = 8.5 Hz, 1H), 7.45 (t, J = 8.1 Hz, 1H), 7.11–7.01 (m, 3H), 6.66 (s, 1H), 6.44 (dd, J = 17.0, 10.1 Hz, 1H), 6.27 (dd, J = 17.0, 1.9 Hz, 1H), 5.82–5.75 (m, 1H), 3.86 (s, 6H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 163.6, 163.3, 163.0, 161.1, 154.6, 152.5, 151.9, 140.3, 134.0, 131.6, 129.9, 127.3, 120.8, 116.8, 116.8, 116.3, 112.7, 104.8, 102.0, 55.6; HPLC: room temperature, t_g = 11.25 min, UV₃₀₀ = 96%; HRMS (ESI) m/z calcd for chemical formula: C₂₃H₁₉N₃O₄S [M + Na]⁺: 456.0994, found: 456.1017.

3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)aniline (10a). From compound 2 (176 mg, 0.5 mmol) and (2,6-dichloro-3,5-dimethoxyphenyl)boronic acid (188 mg, 0.75 mmol), as that described in step 1, gave 10a (117 mg, 52%); white solid; mp: 199.1–200.5 °C; ^1H NMR (400 MHz, CDCl₃) δ 8.77 (s, 1H), 7.43 (s, 1H), 7.27–7.22 (m, 1H), 6.70 (s, 1H), 6.68–6.64 (m, 1H), 6.61 (dt, J = 4.4, 1.7 Hz, 2H), 3.99 (s, 6H); ^{13}C NMR (101 MHz, CDCl₃) δ 163.9, 162.7, 154.8, 154.6, 153.0, 148.0, 147.0, 133.0, 130.4, 125.8, 119.1, 115.5, 113.0, 111.6, 108.4, 98.4, 56.8; ESI-MS: m/z 448.0 [M + H]⁺.

N-(3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide (10). From compound 10a (45 mg, 0.1 mmol), as that described in step 2, gave 10 (18 mg, 36%); white solid; mp: 228.0–228.5 °C; ^1H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 8.77 (s, 1H), 7.79 (s, 1H), 7.70 (s, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.45 (t, J = 8.1 Hz, 1H), 7.14–7.08 (m, 2H), 6.44 (dd, J = 17.0, 10.1 Hz, 1H), 6.27 (dd, J = 17.0, 1.9 Hz, 1H), 5.78 (dd, J = 10.1, 1.9 Hz, 1H), 4.00 (s, 6H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 163.3, 163.2, 162.6, 154.6, 154.5, 151.8, 146.6, 140.3, 131.7, 131.6, 129.9, 127.3, 126.0, 117.9, 117.0, 116.9, 113.5, 112.8, 99.8, 56.9; HPLC: room temperature, t_g = 11.31 min, UV₃₀₀ = 99%; HRMS (ESI) m/z calcd for chemical formula: C₂₃H₁₇Cl₂N₃O₄S [M + Na]⁺: 524.0215, found: 524.0228.

Methyl 4-(4-(3-aminophenoxy)thieno[3,2-d]pyrimidin-6-yl)benzoate (11a). From compound 2 (176 mg, 0.5 mmol) and (4-(methoxycarbonyl)phenyl)boronic acid (135 mg, 0.75 mmol), as that described in step 1, gave 11a (116 mg, 62%); white solid; mp: 201.2.0–201.9 °C; ^1H NMR (400 MHz, DMSO-d₆) δ 8.73 (s, 1H), 8.24 (s, 1H), 8.08 (s, 4H), 7.11 (s, 1H), 6.73–6.20 (m, 3H), 5.35 (s, 2H), 3.90 (s, 3H); ^{13}C NMR (101 MHz, DMSO-d₆) δ 165.5, 163.3, 154.8, 152.7, 150.7, 150.3, 136.4, 130.6, 130.1, 129.8, 126.9, 121.9, 111.6, 108.5, 106.7, 52.4; ESI-MS: m/z 378.1 [M + H]⁺.



Methyl-4-(4-(3-acrylamidophenoxy)thieno[3,2-*d*]pyrimidin-6-yl)benzoate (11). From compound **11a** (38 mg, 0.1 mmol), as that described in step 2, gave **11** (15 mg, 35%); white solid; mp: 220.1–220.9 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.36 (s, 1H), 8.74 (s, 1H), 8.28 (s, 1H), 8.10 (q, *J* = 8.6 Hz, 4H), 7.80 (t, *J* = 1.9 Hz, 1H), 7.53 (d, *J* = 8.7 Hz, 1H), 7.45 (t, *J* = 8.1 Hz, 1H), 7.08 (dd, *J* = 8.0, 1.5 Hz, 1H), 6.44 (dd, *J* = 17.0, 10.1 Hz, 1H), 6.27 (dd, *J* = 17.0, 1.9 Hz, 1H), 5.78 (dd, *J* = 10.1, 1.9 Hz, 1H), 3.90 (s, 3H); ¹³C NMR (101 MHz, DMSO-d₆) δ 165.5, 163.5, 163.3, 163.1, 154.7, 151.8, 150.9, 140.3, 136.3, 131.6, 130.7, 130.1, 129.9, 127.3, 126.9, 121.9, 117.0, 116.9, 116.8, 112.7, 52.4; HPLC: room temperature, *t*_g = 11.08 min, UV₃₀₀ = 97%; HRMS (ESI) *m/z* calcd for chemical formula: C₂₂H₁₇N₃O₃S [M + Na]⁺: 426.0888, found: 426.0898.

3-((6-([1,1'-Biphenyl]-4-yl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)aniline (12a). From compound **2** (176 mg, 0.5 mmol) and [1,1'-biphenyl]-4-ylboronic acid (149 mg, 0.75 mmol), as that described in step 1, gave **12a** (108 mg, 55%); white solid; mp: 216.2–217.3 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.65 (s, 1H), 7.77 (d, *J* = 5.5 Hz, 2H), 7.65 (s, 3H), 7.57 (d, *J* = 4.8 Hz, 2H), 7.40 (s, 2H), 7.33 (d, *J* = 4.9 Hz, 1H), 7.17 (d, *J* = 7.0 Hz, 1H), 6.54 (d, *J* = 15.9 Hz, 3H), 3.74 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 163.8, 163.7, 154.9, 153.1, 153.1, 148.0, 142.8, 140.0, 131.9, 130.4, 129.0, 128.0, 127.9, 119.7, 117.5, 112.9, 111.6, 108.4; ESI-MS: *m/z* 395.9 [M + H]⁺.

N-(3-((6-([1,1'-Biphenyl]-4-yl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)phenyl)acrylamide (12). From compound **12a** (45 mg, 0.1 mmol), as that described in step 2, gave **12** (14 mg, 31%); white solid; mp: 248.5–249.1 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 8.72 (s, 1H), 8.20 (s, 1H), 8.07 (d, *J* = 8.3 Hz, 2H), 7.87 (d, *J* = 8.3 Hz, 2H), 7.82–7.77 (m, 2H), 7.77 (s, 1H), 7.56–7.52 (m, 2H), 7.49 (d, *J* = 9.8 Hz, 1H), 7.47–7.38 (m, 2H), 7.09 (dd, *J* = 8.0, 1.3 Hz, 1H), 6.44 (dd, *J* = 17.0, 10.1 Hz, 1H), 6.27 (dd, *J* = 17.0, 1.7 Hz, 1H), 5.81–5.74 (m, 1H); ¹³C NMR (101 MHz, DMSO-d₆) δ 163.8, 163.4, 163.0, 154.6, 152.2, 151.9, 141.8, 140.3, 138.9, 131.6, 131.1, 129.9, 129.1, 128.1, 127.6, 127.3, 127.2, 126.7, 120.2, 116.9, 116.8, 116.3, 112.7; HPLC: room temperature, *t*_g = 12.92 min, UV₃₀₀ = 98%; HRMS (ESI) *m/z* calcd for chemical formula: C₂₇H₁₉N₃O₂S [M + Na]⁺: 472.1096, found: 472.1112.

3-((6-(4-Methoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)aniline (13a). From compound **2** (176 mg, 0.5 mmol) and (4-methoxyphenyl)boronic acid (114 mg, 0.75 mmol), as that described in step 1, gave **13a** (102 mg, 58%); white solid; mp: 194.8–195.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H), 7.71 (d, *J* = 8.3 Hz, 2H), 7.59 (s, 1H), 7.23 (t, *J* = 8.0 Hz, 1H), 7.00 (d, *J* = 8.3 Hz, 2H), 6.62 (dd, *J* = 18.7, 8.2 Hz, 3H), 3.88 (s, 3H), 3.82 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 164.1, 163.6, 161.1, 154.8, 153.5, 153.2, 148.0, 130.3, 128.2, 125.6, 118.4, 117.0, 114.7, 112.9, 111.6, 108.4, 55.5; ESI-MS: *m/z* 350.1 [M + H]⁺.

N-(3-((6-(4-Methoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)phenyl)acrylamide (13). From compound **13a** (35 mg, 0.1 mmol), as that described in step 2, gave **13** (11 mg, 27%); yellow solid; mp: 229.1–229.8 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.43 (s, 1H), 7.99 (s, 1H), 7.90 (d, *J* = 8.7 Hz, 2H), 7.77 (s, 1H), 7.54 (d, *J* = 8.5 Hz, 1H), 7.43 (t, *J* = 8.1 Hz, 1H), 7.10 (d, *J* = 8.7 Hz, 2H), 7.05 (dd, *J* = 8.0, 1.5 Hz, 1H), 6.46 (dd, *J* = 17.0, 10.1 Hz, 1H),

6.26 (dd, *J* = 17.0, 1.7 Hz, 1H), 5.78–5.71 (m, 1H), 3.84 (s, 3H); ¹³C NMR (101 MHz, DMSO-d₆) δ 163.4, 160.9, 152.8, 151.9, 140.3, 131.6, 129.9, 128.2, 127.3, 124.6, 116.9, 116.7, 114.8, 112.7, 55.4; HPLC: room temperature, *t*_g = 10.98 min, UV₃₀₀ = 97%; HRMS (ESI) *m/z* calcd for chemical formula: C₂₂H₁₇N₃O₃S [M + Na]⁺: 426.0888, found: 426.0898.

1-(6-(4-Phenoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-amine (14a). From compound **3** (189 mg, 0.5 mmol) and (4-phenoxyphenyl)boronic acid (161 mg, 0.75 mmol), as that described in step 1, gave **14a** (116 mg, 53%); yellow solid; mp: 205.2–206.3 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (s, 1H), 8.21 (s, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.86 (s, 1H), 7.46 (t, *J* = 7.7 Hz, 2H), 7.23 (t, *J* = 7.3 Hz, 1H), 7.17 (d, *J* = 7.9 Hz, 1H), 7.15–7.09 (m, 4H), 6.68 (d, *J* = 7.5 Hz, 1H), 4.70 (s, 2H), 3.24 (t, *J* = 7.8 Hz, 2H); HRMS (ESI) *m/z* calcd for chemical formula: C₂₆H₂₀N₄OS [M + H]⁺: 437.1436, found: 437.1418.

N-(1-(6-(4-Phenoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-yl)acrylamide (14). From compound **14a** (43 mg, 0.1 mmol), as that described in step 2, gave **14** (17 mg, 35%); yellow solid; mp: 246.9–247.3 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.15 (s, 1H), 8.65 (d, *J* = 16.5 Hz, 2H), 7.93 (d, *J* = 8.6 Hz, 2H), 7.86 (s, 1H), 7.54 (d, *J* = 8.2 Hz, 1H), 7.46 (t, *J* = 7.8 Hz, 2H), 7.28–7.19 (m, 2H), 7.12 (d, *J* = 6.6 Hz, 4H), 6.48 (dd, *J* = 17.0, 10.1 Hz, 1H), 6.26 (d, *J* = 16.9 Hz, 1H), 5.74 (d, *J* = 10.3 Hz, 1H), 4.73 (t, *J* = 8.2 Hz, 2H), 3.26 (d, *J* = 8.0 Hz, 2H); HPLC: room temperature, *t*_g = 10.46 min, UV₃₆₅ = 96%; HRMS (ESI) *m/z* calcd for chemical formula: C₂₉H₂₂N₄O₂S [M + Na]⁺: 513.1361, found: 513.1360.

1-(6-(4-(Methylsulfonyl)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-amine (15a). From compound **3** (189 mg, 0.5 mmol) and (4-(methylsulfonyl)phenyl)boronic acid (150 mg, 0.75 mmol), as that described in step 1, gave **15a** (106 mg, 50%); yellow solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.65 (s, 1H), 8.20 (d, *J* = 8.5 Hz, 2H), 8.15 (s, 1H), 8.10 (s, 1H), 8.06 (d, *J* = 8.4 Hz, 2H), 7.11 (d, *J* = 7.9 Hz, 1H), 6.55 (d, *J* = 7.8 Hz, 1H), 4.74 (t, *J* = 8.0 Hz, 2H), 3.30 (s, 3H), 3.26–3.19 (m, 2H); HRMS (ESI) *m/z* calcd for chemical formula: C₂₁H₁₈N₄O₂S₂ [M + H]⁺: 423.0949, found: 423.0970.

N-(1-(6-(4-(Methylsulfonyl)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-yl)acrylamide (15). From compound **15a** (42 mg, 0.1 mmol), as that described in step 2, gave **15** (19 mg, 40%); yellow solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.16 (s, 1H), 8.71 (s, 1H), 8.66 (s, 1H), 8.18 (d, *J* = 8.3 Hz, 2H), 8.13 (s, 1H), 8.05 (d, *J* = 8.3 Hz, 2H), 7.54 (d, *J* = 7.8 Hz, 1H), 7.23 (d, *J* = 8.1 Hz, 1H), 6.49 (dd, *J* = 16.9, 10.1 Hz, 1H), 6.26 (d, *J* = 17.1 Hz, 1H), 5.74 (d, *J* = 9.3 Hz, 1H), 4.75 (t, *J* = 8.3 Hz, 2H), 3.29 (s, 3H), 3.26 (d, *J* = 8.2 Hz, 2H); ¹³C NMR (101 MHz, DMSO-d₆) δ 163.0, 161.6, 154.9, 154.0, 147.4, 143.5, 141.3, 137.8, 136.8, 132.0, 128.0, 127.5, 127.1, 126.5, 124.5, 122.6, 116.2, 114.6, 109.1, 50.2, 43.4, 27.4; HPLC: room temperature, *t*_g = 7.86 min, UV₃₆₅ = 97%; HRMS (ESI) *m/z* calcd for chemical formula: C₂₄H₂₀N₄O₃S₂ [M + Na]⁺: 499.0875, found: 499.0898.

1-(6-(3,5-Dimethoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-amine (16a). From compound **3** (189 mg, 0.5 mmol) and (3,5-dimethoxyphenyl)boronic acid (137 mg, 0.75 mmol), as that described in step 1, gave **16a** (105 mg, 52%); yellow solid; mp: 242.1–243.2 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.67 (s, 1H), 8.38 (s, 1H), 8.00 (s, 1H), 7.27 (d, *J* = 7.8 Hz, 1H), 7.04 (s, 2H),



6.84 (d, $J = 7.6$ Hz, 1H), 6.63 (s, 1H), 4.76 (t, $J = 8.0$ Hz, 2H), 3.85 (s, 6H), 3.30 (t, $J = 8.1$ Hz, 2H); HRMS (ESI) m/z calcd for chemical formula: $C_{22}H_{20}N_4O_2S$ [M + H]⁺: 405.1385, found: 405.1408.

N-(1-(6-(3,5-Dimethoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-yl)acrylamide (16). From compound **16a** (40 mg, 0.1 mmol), as that described in step 2, gave **16** (17 mg, 37%); yellow solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.21 (s, 1H), 8.74 (s, 1H), 8.69 (s, 1H), 8.04 (s, 1H), 7.60 (d, $J = 8.0$ Hz, 1H), 7.28 (d, $J = 8.1$ Hz, 1H), 7.09 (d, $J = 1.8$ Hz, 2H), 6.68 (s, 1H), 6.54 (dd, $J = 16.9, 10.1$ Hz, 1H), 6.32 (d, $J = 16.9$ Hz, 1H), 5.81 (s, 1H), 4.79 (t, $J = 8.3$ Hz, 2H), 3.90 (s, 6H), 3.32 (d, $J = 8.3$ Hz, 2H); HPLC: room temperature, $t_g = 9.27$ min, UV₃₂₀ = 96%; HRMS (ESI) m/z calcd for chemical formula: $C_{25}H_{22}N_4O_3S$ [M + Na]⁺: 481.1310, found: 481.1306.

1-(6-(4-Methoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-amine (17a). From compound **3** (189 mg, 0.5 mmol) and (4-methoxyphenyl)boronic acid (114 mg, 0.75 mmol), as that described in step 1, gave **17a** (115 mg, 61%); yellow solid; mp: 226.5–227.2 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (s, 1H), 8.18 (s, 1H), 7.85 (s, 3H), 7.14 (s, 1H), 7.08 (s, 2H), 6.66 (s, 1H), 4.67 (s, 2H), 3.83 (s, 3H), 3.23 (s, 2H); HRMS (ESI) m/z calcd for chemical formula: $C_{21}H_{18}N_4OS$ [M + H]⁺: 375.1280, found: 375.1306.

N-(1-(6-(4-Methoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-yl)acrylamide (17). From compound **17a** (37 mg, 0.1 mmol), as that described in step 2, gave **17** (21 mg, 49%); off-white solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.38 (s, 1H), 8.73 (s, 1H), 8.61 (s, 1H), 7.86 (d, $J = 8.5$ Hz, 2H), 7.80 (s, 1H), 7.54 (d, $J = 7.7$ Hz, 1H), 7.22 (d, $J = 8.0$ Hz, 1H), 7.08 (d, $J = 8.5$ Hz, 2H), 6.57 (dd, $J = 17.0, 10.3$ Hz, 1H), 6.25 (d, $J = 16.9$ Hz, 1H), 5.72 (d, $J = 10.3$ Hz, 1H), 4.72 (t, $J = 8.2$ Hz, 2H), 3.84 (s, 3H), 3.27 (t, $J = 8.3$ Hz, 2H); HPLC: room temperature, $t_g = 9.02$ min, UV₃₆₅ = 95%; HRMS (ESI) m/z calcd for chemical formula: $C_{24}H_{20}N_4O_2S$ [M + Na]⁺: 451.1205, found: 451.1227.

1-(6-([1,1'-Biphenyl]-4-yl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-amine (18a). From compound **3** (189 mg, 0.5 mmol) and [1,1'-biphenyl]-4-ylboronic acid (149 mg, 0.75 mmol), as that described in step 1, gave **18a** (113 mg, 54%); yellow solid; mp: 245.2–246.1 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (s, 1H), 8.17 (s, 1H), 7.99 (d, $J = 7.7$ Hz, 3H), 7.83 (d, $J = 7.9$ Hz, 2H), 7.75 (d, $J = 7.7$ Hz, 2H), 7.51 (t, $J = 7.5$ Hz, 2H), 7.42 (t, $J = 7.3$ Hz, 1H), 7.13 (d, $J = 7.8$ Hz, 1H), 6.63 (d, $J = 7.6$ Hz, 1H), 4.71 (s, 2H), 3.23 (t, $J = 8.0$ Hz, 2H); ¹³C NMR (101 MHz, DMSO-d₆) δ 149.4, 144.1, 141.4, 140.1, 139.0, 131.1, 129.0, 128.0, 127.5, 126.8, 126.6, 125.0, 112.7, 107.5, 50.4, 27.2; ESI-MS: m/z 421.1 [M + H]⁺.

N-(1-(6-([1,1'-Biphenyl]-4-yl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-yl)acrylamide (18). From compound **18a** (42 mg, 0.1 mmol), as that described in step 2, gave **18** (23 mg, 49%); yellow solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.21 (s, 1H), 8.66 (d, $J = 17.3$ Hz, 2H), 8.01 (d, $J = 8.4$ Hz, 3H), 7.84 (d, $J = 7.7$ Hz, 2H), 7.77 (d, $J = 7.7$ Hz, 2H), 7.58–7.49 (m, 3H), 7.42 (t, $J = 7.3$ Hz, 1H), 7.23 (d, $J = 7.9$ Hz, 1H), 6.50 (dd, $J = 16.7, 10.0$ Hz, 1H), 6.26 (d, $J = 16.9$ Hz, 1H), 5.74 (d, $J = 10.2$ Hz, 1H), 4.76 (t, $J = 8.2$ Hz, 2H), 3.30–3.25 (m, 2H); HPLC: room temperature, $t_g = 13.25$ min, UV₃₂₀ = 97%; HRMS (ESI) m/z calcd for chemical formula: $C_{29}H_{22}N_4OS$ [M + Na]⁺: 497.1412, found: 497.1398.

1-(6-(4-(2-Methoxyethoxy)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-amine (19a). From compound **3** (189 mg, 0.5 mmol) and 2-(4-(2-methoxyethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (209 mg, 0.75 mmol), as that described in step 1, gave **19a** (107 mg, 51%); yellow solid; mp: 237.2–237.9 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.61 (s, 1H), 8.20 (s, 1H), 7.82 (s, 3H), 7.16 (d, $J = 7.4$ Hz, 1H), 7.08 (d, $J = 6.0$ Hz, 2H), 6.67 (d, $J = 7.2$ Hz, 1H), 4.66 (s, 2H), 4.17 (d, $J = 2.3$ Hz, 2H), 3.68 (s, 2H), 3.32 (s, 3H), 3.24 (s, 2H); ¹³C NMR (101 MHz, DMSO-d₆) δ 159.9, 150.2, 144.1, 127.8, 125.0, 124.6, 115.2, 113.3, 108.1, 70.2, 67.2, 58.2, 50.4, 27.2; ESI-MS: m/z 419.1 [M + H]⁺.

N-(1-(6-(4-(2-Methoxyethoxy)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-yl)acrylamide (19). From compound **19a** (42 mg, 0.1 mmol), as that described in step 2, gave **19** (17 mg, 36%); yellow solid; mp: 245.1–246.0 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.19 (s, 1H), 8.66 (s, 1H), 8.61 (s, 1H), 7.84 (d, $J = 8.7$ Hz, 2H), 7.81 (s, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.22 (d, $J = 8.1$ Hz, 1H), 7.09 (d, $J = 8.7$ Hz, 2H), 6.49 (dd, $J = 16.9, 10.1$ Hz, 1H), 6.25 (dd, $J = 16.9, 1.8$ Hz, 1H), 5.74 (dd, $J = 10.1, 1.8$ Hz, 1H), 4.72 (t, $J = 8.3$ Hz, 2H), 4.22–4.13 (m, 2H), 3.72–3.66 (m, 2H), 3.26 (t, $J = 8.3$ Hz, 3H); ¹³C NMR (101 MHz, DMSO-d₆) δ 163.0, 162.2, 159.8, 154.7, 153.8, 149.9, 143.6, 137.7, 132.0, 127.8, 127.3, 126.5, 124.7, 124.5, 118.7, 115.2, 114.6, 114.3, 108.8, 70.3, 67.2, 58.2, 50.2, 27.4; HPLC: room temperature, $t_g = 8.57$ min, UV₃₂₀ = 96%; HRMS (ESI) m/z calcd for chemical formula: $C_{26}H_{24}N_4O_3S$ [M + Na]⁺: 495.1467, found: 495.1479.

1-(6-(4-Morpholinophenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-amine (20a). From compound **3** (189 mg, 0.5 mmol) and 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine (217 mg, 0.75 mmol), as that described in step 1, gave **20a** (112 mg, 52%); dark red solid; mp: >250 °C; ¹H NMR (400 MHz, D₂O + CF₃COOD) δ 7.68–7.56 (m, 2H), 6.81 (d, $J = 7.5$ Hz, 2H), 6.64 (s, 1H), 6.57 (d, $J = 8.1$ Hz, 2H), 6.27 (d, $J = 6.6$ Hz, 1H), 6.08 (d, $J = 6.9$ Hz, 1H), 3.69 (s, 2H), 2.99 (s, 4H), 2.54 (s, 4H), 2.27 (s, 2H); HRMS (ESI) m/z calcd for chemical formula: $C_{24}H_{23}N_5OS$ [M + H]⁺: 430.1702, found: 430.1707.

N-(1-(6-(4-Morpholinophenyl)thieno[3,2-*d*]pyrimidin-4-yl)indolin-6-yl)acrylamide (20). From compound **20a** (43 mg, 0.1 mmol), as that described in step 2, gave **20** (19 mg, 39%); yellow solid; mp: >250 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 10.18 (s, 1H), 8.65 (s, 1H), 8.59 (s, 1H), 7.77 (s, 1H), 7.74 (d, $J = 4.9$ Hz, 2H), 7.55 (d, $J = 7.8$ Hz, 1H), 7.22 (d, $J = 8.1$ Hz, 1H), 7.05 (d, $J = 8.6$ Hz, 2H), 6.49 (dd, $J = 16.9, 10.1$ Hz, 1H), 6.26 (d, $J = 16.7$ Hz, 1H), 5.74 (d, $J = 10.8$ Hz, 1H), 4.71 (t, $J = 8.2$ Hz, 2H), 3.75 (s, 4H), 3.29–3.18 (m, 6H); HPLC: room temperature, $t_g = 8.63$ min, UV₃₂₀ = 95%; HRMS (ESI) m/z calcd for chemical formula: $C_{27}H_{25}N_5O_2S$ [M + H]⁺: 484.1807, found: 484.1815.

TR-FRET LanthaScreen assay (enzyme inhibition assay)

Firstly, we optimized the LanthaScreen™ kinase assay for BTK (ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer's specifications. TR-FRET assays were performed by incubating a diluted series of compound concentrations with ATP (ThermoFisher Scientific), fluorescein-poly GT substrate (ThermoFisher Scientific) and BTK Kinase (ThermoFisher Scientific) in kinase reaction buffer (ThermoFisher Scientific).



The kinase reaction buffer consisted of 50 mM HEPES pH 7.5, 0.01% Brij-35, 10 mM MgCl₂, and 1 mM EGTA. The kinase reaction mixtures were incubated at room temperature (23 ± 2 °C) for 1 h before stopping the kinase reaction by the addition of 10 mM EDTA (ThermoFisher Scientific). The phosphorylation of the substrate by BTK was detected using Tb-PY20 antibody (ThermoFisher Scientific) in TR-FRET dilution buffer at pH 7.5 (ThermoFisher Scientific) and then measured by determining the emission ratio of 520/495 nm on an microplate reader (SpectraMax M5, Molecular Devices). IC₅₀ was estimated using the log(inhibitor) vs. response non-linear fit (GraphPad Prism 6.0). Additional assays were similarly carried out to determine selectivity over EGFR (ThermoFisher Scientific).

Animals

Inbred 6–8 week-old female BALB/c mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd. (certificate no. 2013-0018, Shanghai, China). Normal BALB/c mice ($n = 6$) were used for preparation of splenocytes and all mice were raised under specific pathogen-free conditions and kept in a 12 h light/dark cycle with controlled humidity (60–80%) and temperature (22 ± 1 °C). Experiments were carried out according to the National Institutes of Health Guides for the Care and Use of Laboratory Animals and were approved by the Bioethics Committee of the Shanghai Institute of Materia Medica Sciences.

Cell viability assay

Preparation of splenocytes from BALB/c mice was performed as previously described.⁵¹ Splenocytes (1×10^6 cells) were cultured in 96-well plates in triplicate with 200 µL RPMI 1640 media containing 10% FBS, penicillin (100 U mL⁻¹), and streptomycin (100 µg mL⁻¹) in a humidified, 37 °C, 5% CO₂-containing incubator for 48 h in the presence or absence of indicated concentrations of compounds. A total of 20 µL CCK-8 was added to each well. After 6–8 h incubation, the absorbance value at 450 nm (570 nm calibration) was measured using a microplate reader (Molecular Devices, Sunnyvale, CA, USA) and the cell viability was calculated.

Proliferation responses of murine lymphocytes

Splenocytes (5×10^5 cells) were cultured in triplicate for 48 h with 5 µg mL⁻¹ of ConA (Sigma-Aldrich, St Louis, MO) or 10 µg mL⁻¹ of LPS (Sigma-Aldrich) in the presence or absence of indicated concentrations of compounds. Cells were pulsed with 0.5 µCi per well of [³H]-thymidine (Perkin Elmer, MA, USA) for 8 h and harvested. The incorporated radioactivity was then counted using a Beta Scintillation Counter (MicroBeta Trilux, Perkin Elmer Life Sciences, Boston, MA). The IC₅₀ was estimated using the log(inhibitor) vs. response non-linear fit (GraphPad Prism 6.0).

In vitro enzymatic screen assays

The selectivity of attractive compounds for BTK and non-BTK kinases was determined by testing the compounds at a single

200 nM concentration against a panel of 25 kinases using the Caliper assay at Shanghai ChemPartner Co. Ltd (Shanghai, China). Firstly, the compounds were incubated at the final concentration of 200 nM with ATP, enzyme and FAM-labeled peptide in kinase base buffer. The kinase base buffer contained 50 mM HEPES (pH 7.5), 0.0015% Brij-35, 10 mM MgCl₂ and 2 mM DTT. The kinase reaction mixtures were then incubated at 28 °C for a specified period of time. Finally, 25 µL of stop buffer was added to stop the reaction. The stop buffer consisted of 100 mM HEPES (pH 7.5), 0.015% Brij-35, 0.2% coating reagent #3 and 50 mM EDTA. Data was collected on a Caliper and the conversion data copied from the Caliper program. The inhibition rate was calculated using following formula: percent inhibition = (max – conversion)/(max – min) × 100, where, max stands for the DMSO control and min stands for the low control.

Acknowledgements

This work was supported by the “Personalized Medicines—Molecular Signature-based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences, Grant No. XDA12020337.

Notes and references

- 1 C. I. Edvard Smith, T. C. Islam, P. T. Mattsson, A. J. Mohamed and B. F. Nore, *BioEssays*, 2001, **23**, 436–446.
- 2 J. G. Rodriguez, J. A. Readinger, I. C. Viorritto, K. L. Mueller, R. A. Houghtling and P. L. Schwartzberg, *Immunol. Rev.*, 2007, **218**, 45–64.
- 3 S. Tsukada, D. C. Saffran, D. J. Rawlings, O. Parolini, R. C. Allen, I. Klisak, R. S. Sparkes, H. Kubagawa, T. Mohandas, S. Quan, J. W. Belmont, M. D. Cooper, M. E. Conley and O. N. Witte, *Cell*, 1993, **72**, 279–290.
- 4 D. Vtrie, I. Vorechovsky, P. Sideras, J. Holland, A. Davies, F. Flinter, L. Hammarstrom, C. Kinnon, R. Levinsky, M. Bobrow, C. I. Edvard Smith and D. R. Bentley, *Nature*, 1993, **361**, 226–233.
- 5 M. de Weers, M. C. Verschuren, M. E. Kraakman, R. G. Mensink, R. K. Schuurman, J. J. van Dongen and R. W. Hendriks, *Eur. J. Immunol.*, 1993, **23**, 3109–3114.
- 6 C. Brunner, B. Muller and T. Wirth, *Histol. Histopathol.*, 2005, **20**, 945–955.
- 7 A. J. Mohamed, L. Yu, C. Bäckesjö, L. V. R. Faryal, A. Aints, B. Christensson, A. Berglöf, M. Vihtinen, B. F. Nore and C. I. Edvard Smith, *Immunol. Rev.*, 2009, **228**, 58–73.
- 8 J. A. Woyach, E. Bojnik, A. S. Ruppert, M. R. Stefanovski, V. M. Goett, K. A. Smucker, L. L. Smith, J. A. Dubovsky, *et al.*, *Blood*, 2014, **123**, 1207–1213.
- 9 S. Ponader, S. S. Chen, J. J. Buggy, K. Balakrishnan, V. Gandhi, W. G. Wierda, M. J. Keatin, *et al.*, *Blood*, 2012, **119**, 1182–1189.
- 10 H. Mueller, A. Stadtmann, H. V. Aken, E. Hirsch, D. Wang, K. Ley and A. Zarbock, *Blood*, 2010, **115**, 3118–3127.
- 11 C. U. Niemann and A. Wiestner, *Semin. Cancer Biol.*, 2013, **23**, 410–421.

12 L. Ren, A. Campbell, H. Q. Fang, S. Gautam, S. Elavazhagan, K. Fatehchand, *et al.*, *J. Biol. Chem.*, 2016, **291**, 3043–3052.

13 J. A. Burger, *Curr. Hematol. Malig. Rep.*, 2014, **9**, 44–49.

14 Y. Lou, Z. K. Sweeney, A. Kuglstatter, D. Davis, D. M. Goldstein, X. C. Han, J. Hong, B. Kocer, R. K. Kondru, *et al.*, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 367–371.

15 E. K. Evans, R. Tester, S. Aslanian, R. Karp, M. Sheets, M. T. Labenski, *et al.*, *J. Pharmacol. Exp. Ther.*, 2013, **346**, 219–228.

16 Q. J. Liu, D. G. Batt, J. S. Lippy, N. Surti, A. J. Tebben, J. K. Muckelbauer, *et al.*, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 4265–4269.

17 H. L. Gardner, B. K. Harrington, R. Izumi, A. Hamdy, A. Kaptein, B. V. Lith, C. A. London, J. C. Byrd, A. J. Johnson and W. C. Kisseberth, *AACR Annual Meeting*, San Diego, CA, April 5–9, 2014.

18 X. L. Gao, J. Wang, J. Liu, D. Guiadeen, A. Krikorian, S. B. Boga, *et al.*, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 1471–1477.

19 D. Zhao, S. S. Huang, M. H. Qu, C. Y. Wang, Z. H. Liu, Z. Li, J. Y. Peng, K. X. Liu, Y. X. Li, X. D. Ma and X. H. Shu, *Eur. J. Med. Chem.*, 2017, **126**, 444–455.

20 E. D. Deeks, *Drugs*, 2017, **77**, 225–236.

21 Y. Zou, J. Xiao, Z. Tu, Y. Zhang, K. Yao, M. Luo, K. Ding, Y. Zhang and Y. Lai, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 3052–3059.

22 L. A. Honigberg, A. M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, S. Li, Z. Pan, D. H. Thamm, R. A. Miller and J. J. Buggy, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 13075–13080.

23 A. Akinleye, Y. M. Chen, N. Mukhi, Y. P. Song and D. L. Liu, *J. Hematol. Oncol.*, 2013, **6**, 59.

24 Y. Ge, Y. Jin, C. Y. Wang, J. B. Zhang, Z. Y. Tang, J. Y. Peng, K. X. Liu, Y. X. Li, Y. W. Zhou and X. D. Ma, *ACS Med. Chem. Lett.*, 2016, **7**, 1050–1055.

25 G. López-Herrera, A. Vargas-Hernández, M. E. González-Serrano, L. Berrón-Ruiz, J. C. Rodríguez-Alba, F. Espinosa-Rosales and L. Santos-Argumedo, *J. Leukocyte Biol.*, 2014, **95**, 243–250.

26 A. D. Chu and B. Y. Chang, *OA Arthritis*, 2013, **1**, 17–23.

27 P. Norman, *Expert Opin. Invest. Drugs*, 2016, **25**, 891–899.

28 J. Liu, D. Guiadeen, A. Krikorian, X. L. Gao, J. Wang, S. B. Boga, *et al.*, *ACS Med. Chem. Lett.*, 2016, **7**, 198–203.

29 D. G. Xu, Y. Kim, J. Postelnek, M. D. Vu, D. Q. Hu, C. Liao, M. Bradshaw, *et al.*, *J. Pharmacol. Exp. Ther.*, 2012, **341**, 90–103.

30 Y. Lou, X. C. Han, A. Kuglstatter, R. K. Kondru, Z. K. Sweeney, M. Soth, J. McIntosh, *et al.*, *J. Med. Chem.*, 2015, **58**, 512–516.

31 C. R. Smith, D. R. Dougan, M. Komandla, T. Kanouni, B. M. Knight, J. D. Lawson, M. Sabat, E. R. Taylor, P. Vu and C. Wyrick, *J. Med. Chem.*, 2015, **58**, 5437–5444.

32 K. H. Kim, A. Maderna, M. E. Schnute, M. Hegen, S. Mohan, J. Miyashiro, L. Lin, E. Li, S. Keegan, J. Lussier, C. Wrocklage, *et al.*, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 6258–6263.

33 Q. Shi, A. Tebben, A. J. Dyckman, H. Li, C. J. Liu, J. Lin, S. Spergel, J. R. Burke, K. W. McIntyre, G. C. Olini, *et al.*, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 2206–2211.

34 J. S. Lee, K. Park, J. Y. Han, K. H. Lee, J. H. Kim, E. K. Cho, J. Y. Cho, Y. J. Min, J. S. Kim, H. G. Kim, B. S. Kim, J. Jung and D. W. Kim, *Ann. Oncol.*, 2015, **26**(9), ix128–ix129.

35 B. S. Safina, S. Baker, M. Baumgardner, P. M. Blaney, B. K. Chan, Y. H. Chen, M. W. Cartwright, G. Castanedo, C. Chabot, *et al.*, *J. Med. Chem.*, 2012, **55**, 5887–5900.

36 D. P. Sutherlin, D. Sampath, M. Berry, G. Castanedo, Z. G. Chang, I. Chuckowree, J. Dotson, *et al.*, *J. Med. Chem.*, 2010, **53**, 1086–1097.

37 K. W. Temburnikar, S. C. Zimmermann, N. T. Kim, C. R. Ross, C. Gelbmann, C. E. Salomon, G. M. Wilson, J. Balzarini and K. L. Seley-Radtke, *Bioorg. Med. Chem.*, 2014, **22**, 2113–2122.

38 Q. Tan, Z. T. Zhang, J. Hui, Y. Zhao and L. Zhu, *Bioorg. Med. Chem.*, 2014, **22**, 358–365.

39 E. Perspicace, V. Jouan-Hureaux, R. Ragno, F. Ballante, S. Sartini, C. L. Motta, *et al.*, *Eur. J. Med. Chem.*, 2013, **63**, 765–781.

40 J. S. Disch, G. Evindar, C. H. Chiu, C. A. Blum, H. Dai, L. Jin, *et al.*, *J. Med. Chem.*, 2013, **56**, 3666–3679.

41 W. F. Zhu, Y. J. Liu, X. Zhai, X. Wang, Y. Zhu, D. Wu, H. Y. Zhou, P. Gong and Y. F. Zhao, *Eur. J. Med. Chem.*, 2012, **57**, 162–175.

42 Z. J. Liu, S. S. Wu, Y. Wang, R. J. Li, J. Wang, L. H. Wang, Y. F. Zhao and P. Gong, *Eur. J. Med. Chem.*, 2014, **87**, 782–793.

43 A. J. Folkes, K. Ahmadi, W. K. Alderton, S. Alix, S. J. Baker, G. Box, I. S. Chuckowree, *et al.*, *J. Med. Chem.*, 2008, **51**, 5522–5532.

44 M. Hayakawa, H. Kaizawa, H. Moritomo, T. Koizumi, T. Ohishi, M. Okada, M. Ohta, S. Tsukamoto, P. Parker, P. Workman and M. Waterfield, *Bioorg. Med. Chem.*, 2006, **14**, 6847–6858.

45 J. Wang, M. B. Su, T. T. Li, A. H. Gao, W. Yang, L. Sheng, Y. Zang, J. Li and H. Liu, *Eur. J. Med. Chem.*, 2017, **128**, 293–299.

46 S. Bugge, A. F. Buene, N. Jurisch-Yaksi, I. U. Moen, E. M. Skjønsfjell, E. Sundby and B. H. Hoff, *Eur. J. Med. Chem.*, 2016, **107**, 255–274.

47 E. S. Kim, *Drugs*, 2016, **76**, 1153–1157.

48 J. L. Woodring, G. Patel, J. Erath, R. Behera, P. J. Lee, S. E. Leed, A. Rodriguez, R. J. Sciotti, K. Mensa-Wilmot and M. P. Pollastri, *MedChemComm*, 2015, **6**, 339–346.

49 W. Devine, J. L. Woodring, U. Swaminathan, E. Amata, G. Patel, J. Erath, N. E. Roncal, P. J. Lee, S. E. Leed, A. Rodriguez, K. Mensa-Wilmot, R. J. Sciotti and M. P. Pollastri, *J. Med. Chem.*, 2015, **58**, 5522–5537.

50 C. I. Smith, B. Baskin, P. Humire-Greiff, J. N. Zhou, P. G. Olsson, H. S. Maniar, P. Kjellén, J. D. Lambris, B. Christensson and L. Hammarström, *J. Immunol.*, 1994, **152**, 557–565.

51 R. Zhou, F. Zhang, P. L. He, *et al.*, *Int. Immunopharmacol.*, 2005, **5**, 1895–1903.

